April 30, 2008
Procter & Gamble Profit Up 8%
By THE ASSOCIATED PRESS
Filed at 10:37 a.m. ET
CINCINNATI (AP) -- Consumer products maker Procter & Gamble Co. said Wednesday price increases and cost controls helped offset higher commodity costs as its third quarter profit rose 8 percent.
P&G also lifted its full-year outlook, and its shares rose almost 3 percent in morning tradiung.
The maker of Pampers diapers and Gillette razors reported profit of $2.71 billion, or 82 cents per share, for the January-March period compared with $2.51 billion, or 74 cents per share, a year ago.
Revenue rose 9 percent to $20.46 billion from $18.69 billion last year.
Analysts predicted profit of 81 cents per share on revenue of $20.43 billion, according to Thomson Financial.
The company now expects fiscal 2008 earnings to be between $3.48 and $3.50, from previous guidance of $3.46 to $3.50 per share. Analysts expect $3.49 per share.
For the first nine months of its fiscal year, the company earned $9.06 billion, or $2.72 a share, up from $8.07 billion, or $2.37 a share, a year earlier. Nine-month revenue rose to $62.2 billion from $57.2 billion a year ago.
The company cited continued double-digit volume growth in developing markets and strong growth among key brands such as Pampers diapers, Gillette Fusion razors and Head & Shoulders shampoo. P&G projected that Fusion, the five-blade razor system introduced two years ago, will top $1 billion in sales for the fiscal year, making it P&G's 24th billion-dollar brand and the fastest ever to reach that level.
''This quarter is yet another demonstration of the power of P&G's product category and geographic diversification and disciplined focus on cash and cost productivity,'' A.G. Lafley, chairman and chief executive officer, said in a statement, adding that P&G delivered strong results ''in a challenging economic and competitive environment.''
Its shares rose $1.72, or 2.6 percent, to $67.62 in morning trading.
|
February 28, 2008
Procter and Gamble Wins Case
Huge Setback for America's Ill
CINCINNATI February 28, 2008 Today the United States District Court of Delaware ruled in favor of The Procter & Gamble Company (P&G) in the patent infringement lawsuit filed by P&G against Teva Pharmaceuticals USA, Inc. The positive ruling protects P&Gs rights in the U.S. to exclusively market the osteoporosis therapy Actonel® (risedronate sodium tablets).
On August 13, 2004 P&G filed a patent infringement lawsuit against Teva to enforce P&Gs U.S. composition of matter patent for risedronate, the active ingredient in Actonel. Teva was seeking to market a generic version of Actonel in the United States under the assertion that the Actonel patent was not valid due to obviousness of the invention. Todays Court ruling upheld the P&G patent, expressly rejecting Tevas validity challenge.
"We are pleased that the Court recognized and acknowledged the uniqueness of the risedronate molecule," said Tom Finn, P&G President, Global Health Care. "We are very proud of the extensive R&D efforts which brought Actonel to market, providing patients help that they need to manage their osteoporosis and prevent fractures."
The Actonel patent life extends through the end of 2013, excluding any potential extensions. Actonel was approved in 2000 by the U.S. Food and Drug Administration for the prevention and treatment of osteoporosis in postmenopausal women. Actonel is the only oral osteoporosis therapy proven to reduce the risk of vertebral fractures in just one year.P & G spends a fortune for their drug empire while denying sick people meds and squashes the right to compete for generic drugs.
CINCINNATI February 28, 2008 Today the United States District Court of Delaware ruled in favor of The Procter & Gamble Company (P&G) in the patent infringement lawsuit filed by P&G against Teva Pharmaceuticals USA, Inc. The positive ruling protects P & G Pharmaceuticals USA, Inc.
The positive ruling protects P & G 's rights in the US to exclusively market ....
|
|
 |
|
|
Mother and Child. Whether flesh and blood or a depiction of family, Procter and Gamble doesn't give a hoot, they're only concerned about the bottom line. |
|
|
|
|
|